Gilde Healthcare bolsters its Private Equity team in Frankfurt office - Gilde Healthcare

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

July 12, 2022
Utrecht (the Netherlands) and Frankfurt (Germany)

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV.

With the recruitment of Martin von Berg as Investment Manager and Lara Hilgert as Investment Analyst, the firm continues to expand its team in the region, following the arrival Robert Stein as Partner in 2021. Before joining Gilde Healthcare, Martin gained more than 5 years of private equity experience at 3i and Halder, where he was involved in healthcare services transactions. Martin started his career in the investment banking team of Bank of America in Frankfurt after graduating from the University of Mannheim with a MSc in Management. Lara joins Gilde Healthcare after finishing her MSc in Management at the London School of Economics. She successfully completed an internship at Gilde Healthcare last year and gained additional working experience at Roland Berger, Greenhill and PWC.

Gilde Healthcare completed four private equity transactions in Germany in the last 18 months and considers additional hires in the coming period.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.9 billion across two fund strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to pharma, medtech and healthcare. Gilde Healthcare’s Venture&Growth fund invests in therapeutics, medtech and healthtech in Europe and North America. Further information at www.gildehealthcare.com

More news

Hermann Medizintechnik joins SPI – the specialized MedTech CDMO platform sponsored by Gilde Healthcare

Hermann Medizintechnik ("Hermann") has officially joined Gilde Healthcare's group of contract manufacturers for complex surgical instruments and implants ("SPI"), marking another significant milestone for SPI. With Hermann, SPI grows to more than 500 highly skilled...
September 10, 2026

BENTEC Endoscopy joins Gilde Healthcare’s contract manufacturing group for surgical instruments and implants

Gilde Healthcare's group of contract manufacturers for complex surgical instruments and implants ("SPI") is acquiring BENTEC Endoscopy ("BENTEC"). The transaction marks another significant milestone in building a leading group for the contract manufacturing of surgical...
August 27, 2026

Gilde Healthcare company Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and optimisation trial will enrol...
June 11, 2026